Grigorios G Dimas

Dr. Grigorios G Dimas

1st Propaedeutic Medical Department of Internal Medicine, AHEPA University Hospital, Medical School of Aristotle University of Thessaloniki
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ISIoanna Sfakianaki
Ioanna Sfakianaki
Paris BinosParis Binos
Paris Binos
PKPetros D. Karkos
Petros D. Karkos
GDGrigorios G Dimas
Grigorios G Dimas
George K. PsillasGeorge K. Psillas
George K. Psillas
Benign paroxysmal positional vertigo (BPPV) is one of the most common peripheral vestibular dysfunctions encountered in clinical practice. Although the treatment of BPPV is relatively successful, many patients develop recurrence after treatment. Our purpose is to evaluate the mean recurrence rate and risk factors of BPPV after treatment. A review of the literature on the risk factors of BPPV recurrence was performed. A thorough search was conducted using electronic databases, namely Pubmed, CINAHL, Academic Search Complete and Scopus for studies published from 2000 to 2020. Thirty studies were included in this review with 13,358 participants. The recurrence rate of BPPV ranged from 13.7% to 48% for studies with follow-up <1 year, and from 13.3% to 65% for studies with follow-up ≥2 years. Pathophysiologic mechanisms and implication of each of the following risk factors in the recurrence of BPPV were described: advanced age, female gender, Meniere’s disease, trauma, osteopenia or osteoporosis, vitamin D deficiency, diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease, migraine, bilateral/multicanal BPPV, cervical osteoarthrosis and sleep disorders. Patients with hyperlipidemia and hypertension had the highest recurrence rates of BPPV, 67.80% and 55.89%, respectively, indicating that vascular comorbidities increase the risk of BPPV recurrence. In addition, more than half of patients (53.48%) with diabetes mellitus and BPPV experienced recurrence of BPPV. Knowledge and awareness of risk factors for recurrence of BPPV are essential for the assessment and long-term prognosis of patients. Identification of these relapse risk factors may enhance the ability of clinicians to accurately counsel patients regarding BPPV and associated comorbidities.

Verified
Journal Article
Open access
PDF file
George K. PsillasGeorge K. Psillas
George K. Psillas
GDGrigorios G Dimas
Grigorios G Dimas
Anastasia SarafidouAnastasia Sarafidou
Anastasia Sarafidou
TDTriantafyllos Didangelos
Triantafyllos Didangelos
VPVasilios Perifanis
Vasilios Perifanis
JCJiannis Constantinidis
Jiannis Constantinidis
The aim of this study is to evaluate the effects of diabetes mellitus, hypertension and hypercholesterolemia on the clinical presentation and outcome of Bell’s palsy. The study (comorbidity) group consisted of 50 patients with Bell’s palsy associated with diabetes, hypertension, or hypercholesterolemia; the control group included 46 patients with Bell’s palsy, but without comorbid diseases. The House–Brackmann grading system (I to VI) was used in order to assess the initial and final facial functions. Both groups of patients were treated with steroids and the antiviral agent acyclovir. The mean severity of initial facial paralysis was more significant in diabetes, hypercholesterolemia, and hypertension, in comparison to the control group. Patients suffering from Bell’s palsy and concomitant comorbidities have a poorer prognosis (HB III-VI) compared to patients without comorbidities. Increased glycosylated hemoglobin A1c levels (>6.7%) were significantly correlated with unsatisfactory facial recovery. The pathogenetic mechanisms by which diabetes, hypercholesterolemia, and hypertension affect the vasa nervosum of facial nerve have been described.

1 October 2013
Verified
Journal Article
Closed access
GDGrigorios G Dimas
Grigorios G Dimas
FIF Iliadis
F Iliadis
DGD Grekas
D Grekas

25 January 2021 in Audiology Research
Verified
Journal Article
Open access
PDF file
George K. PsillasGeorge K. Psillas
George K. Psillas
Paris BinosParis Binos
Paris Binos
GDGrigorios G Dimas
Grigorios G Dimas
MDMichalis Daniilidis
Michalis Daniilidis
JCJiannis Constantinidis
Jiannis Constantinidis
Background: To evaluate the effect of human leukocyte antigen (HLA) on hearing outcome in patients suffering from autoimmune hearing loss (AIHL). Materials and Methods: The diagnosis of AIHL was essentially based on clinical symptoms, such as recurrent, sudden, fluctuating, or quickly progressing (<12 months) sensorineural hearing loss (uni-/bilateral). The molecular typing of HLA alleles was achieved by using polymerase chain reaction procedures. Patients underwent a tapering schema of steroid treatment and audiometric features were recorded. A logistic regression model was used to identify which HLA typing alleles were statistically significant in patients’ response to treatment. Results: Forty patients with AIHL were found to be carriers of HLA B27, B35, B51, C4, C7, and DRB1*04 alleles. No statistically significant influence of HLA B27, B35, B51, C4, C7, DRB1*04 HLA alleles typing was detected for the prognosis of AIHL. In these patients, the onset of AIHL was mainly progressive (53.8%), 29.2% of them had moderate hearing loss, and most of the cases had both bilateral hearing loss (62.5%) and downsloping audiogram (40%). Conclusion: The presence of HLA B27, B35, B51, C4, C7, and DRB1*04 alleles had no significant effect on a favorable outcome of AIHL. However, larger samples of patients are necessary in order to improve the knowledge about the HLA influence on the clinical course of AIHL.

7 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
George K. PsillasGeorge K. Psillas
George K. Psillas
GDGrigorios G Dimas
Grigorios G Dimas
Christos SavopoulosChristos Savopoulos
Christos Savopoulos
JCJiannis Constantinidis
Jiannis Constantinidis
Autoimmune hearing loss (AIHL) is a clinical disease and may involve the deposition of immune complexes in the labyrinth vessels, the activation of the complement system, the functional alteration in T-cell subpopulations, or an inflammation process in the inner ear

31 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Olga Christos SiskouOlga Christos Siskou
Olga Christos Siskou
Petros GalanisPetros Galanis
Petros Galanis
Olympia KonstantakopoulouOlympia Konstantakopoulou
Olympia Konstantakopoulou
PSPanagiotis C. Stafylas
Panagiotis C. Stafylas
IKIliana Karagouni
Iliana Karagouni
DKDaphne Kaitelidou
Daphne Kaitelidou
The aim of this study was to measure one-year total cost of stroke and to investigate the value of stroke care, defined as cost per QALY. The study population included 892 patients with first ever acute stroke, hemorrhagic and ischemic, (ICD-10 codes: I61, I63 and I64) admitted within 48 hours of symptoms onset to nine public hospitals located in six cities. We conducted a bottom-up cost analysis from the societal point of view. All cost components including direct medical costs, productivity losses due to morbidity and mortality and informal care costs were considered. We used an annual time horizon, including all costs for 2021 irrespective of the time of disease onset. The average cost (direct and indirect) was extrapolated in order to estimate the national annual burden associated with stroke. We estimated the total cost of stroke in Greece at €343.1 mil a year in 2021, (€10,722/patient or €23,308 per QALY). Out of €343.1 mil., 53.3% (€182.9 mil) consisted direct healthcare cost representing 1.1% of current health expenditure in 2021. Overall, productivity losses were calculated at €160.2 mil. The mean productivity losses were estimated to 116 work days with 55.1 days lost due to premature retirement and absenteeism from work, 18.5 days lost due to mortality and 42.4 days lost due to informal caregiving by family members.This study highlights the burden of stroke and underlines the need for stakeholders and policy makers to re-organize stroke care and promote interventions that have been proved as cost-effective